Compare Bristol-Myers Squibb Co (BMY) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Phillips 66 — how do they compare? Bristol-Myers Squibb Co trades at $58.53 (market cap $116.30B), while Phillips 66 trades at $196.84 (market cap $80.77B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PSX | |
|---|---|---|
Market Cap | $116.30B | $80.77B |
Sector | Health | Energy |
52-Week High | $62.37 | $201.45 |
52-Week Low | $42.60 | $118.37 |
Enterprise Value | $152.24B | $102.74B |
Dividend Yield | 4.42% | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Phillips 66 (PSX) trades at $198.29, up 5.27% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 19.59, P/S of 0.6, and ROE of 14.75%, though revenue declined from $170B in 2022 to $132.38B in 2025. Recent earnings beats and consistent dividends of $1.27 quarterly support investor confidence amid refining margin strength.
Outlook remains positive with analyst consensus at Buy (57%) and $201.50 target, though risks include volatile oil prices, declining revenue trends, and high RSI suggesting overbought conditions. The refining sector benefits from Middle East tensions, but execution on cost control and margin stability will dictate near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
